Speer G et al. |
Serum osteoprotegerin level, carotid-femoral pulse wave velocity and cardiovascular survival in haemodialysis patients. |
2008 |
Nephrol. Dial. Transplant. |
pmid:18450827
|
Shroff RC et al. |
The circulating calcification inhibitors, fetuin-A and osteoprotegerin, but not matrix Gla protein, are associated with vascular stiffness and calcification in children on dialysis. |
2008 |
Nephrol. Dial. Transplant. |
pmid:18463323
|
Ford ML et al. |
FGF-23 and osteoprotegerin are independently associated with myocardial damage in chronic kidney disease stages 3 and 4. Another link between chronic kidney disease-mineral bone disorder and the heart. |
2012 |
Nephrol. Dial. Transplant. |
pmid:21750158
|
Schinke T and Karsenty G |
Vascular calcification--a passive process in need of inhibitors. |
2000 |
Nephrol. Dial. Transplant. |
pmid:10978374
|
Cianciolo G et al. |
Effects of unfractioned heparin and low-molecular-weight heparin on osteoprotegerin and RANKL plasma levels in haemodialysis patients. |
2011 |
Nephrol. Dial. Transplant. |
pmid:20659908
|
Sasaki N et al. |
Glucocorticoid decreases circulating osteoprotegerin (OPG): possible mechanism for glucocorticoid induced osteoporosis. |
2001 |
Nephrol. Dial. Transplant. |
pmid:11239019
|
Graciolli FG et al. |
Phosphorus overload and PTH induce aortic expression of Runx2 in experimental uraemia. |
2009 |
Nephrol. Dial. Transplant. |
pmid:19075196
|
Avbersek-Luznik I et al. |
Increased bone resorption in HD patients: is it caused by elevated RANKL synthesis? |
2005 |
Nephrol. Dial. Transplant. |
pmid:15665031
|
Sigrist MK et al. |
Elevated osteoprotegerin is associated with all-cause mortality in CKD stage 4 and 5 patients in addition to vascular calcification. |
2009 |
Nephrol. Dial. Transplant. |
pmid:19491380
|
Messa P et al. |
Calcimimetic increases osteoprotegerin and decreases fetuin-A levels in dialysis patients. |
2007 |
Nephrol. Dial. Transplant. |
pmid:17526536
|
Morena M et al. |
A cut-off value of plasma osteoprotegerin level may predict the presence of coronary artery calcifications in chronic kidney disease patients. |
2009 |
Nephrol. Dial. Transplant. |
pmid:19574342
|
Svensson M et al. |
Osteoprotegerin as a predictor of renal and cardiovascular outcomes in renal transplant recipients: follow-up data from the ALERT study. |
2012 |
Nephrol. Dial. Transplant. |
pmid:22172725
|
Kazama JJ et al. |
Circulating osteoprotegerin is not removed through haemodialysis membrane. |
2002 |
Nephrol. Dial. Transplant. |
pmid:12271009
|
Nitta K et al. |
Serum osteoprotegerin levels and the extent of vascular calcification in haemodialysis patients. |
2004 |
Nephrol. Dial. Transplant. |
pmid:15128884
|
Coen G et al. |
Serum osteoprotegerin and renal osteodystrophy. |
2002 |
Nephrol. Dial. Transplant. |
pmid:11812872
|
Jiang JQ et al. |
Serum osteoprotegerin measurement for early diagnosis of chronic kidney disease-mineral and bone disorder. |
2011 |
Nephrology (Carlton) |
pmid:21649792
|
Ozkaya O et al. |
Osteoprotegerin and RANKL serum levels and their relationship with serum ghrelin in children with chronic renal failure and on dialysis. |
2007 |
Nephron Clin Pract |
pmid:17259742
|
Kim HR et al. |
The ratio of osteoprotegerin to fetuin-a is independently associated with vascular stiffness in hemodialysis patients. |
2013 |
Nephron Clin Pract |
pmid:23921088
|
Kurnatowska I et al. |
Serum osteoprotegerin is a predictor of progression of atherosclerosis and coronary calcification in hemodialysis patients. |
2011 |
Nephron Clin Pract |
pmid:20861651
|
Kao SY et al. |
Loss of osteoprotegerin expression in the inner ear causes degeneration of the cochlear nerve and sensorineural hearing loss. |
2013 |
Neurobiol. Dis. |
pmid:23607938
|
Bergestuen DS et al. |
Activin A in carcinoid heart disease: a possible role in diagnosis and pathogenesis. |
2010 |
Neuroendocrinology |
pmid:20720391
|
Kokkotou E et al. |
Serum correlates of the placebo effect in irritable bowel syndrome. |
2010 |
Neurogastroenterol. Motil. |
pmid:20028464
|
Erdogan B et al. |
Intima-media thickness of the carotid arteries is related to serum osteoprotegerin levels in healthy postmenopausal women. |
2004 |
Neurol. Res. |
pmid:15327755
|
Sen O et al. |
The relation between serum levels of osteoprotegerin and postoperative epidural fibrosis in patients who underwent surgery for lumbar disc herniation. |
2005 |
Neurol. Res. |
pmid:15949247
|
Jefferson AL et al. |
Inflammatory biomarkers are associated with total brain volume: the Framingham Heart Study. |
2007 |
Neurology |
pmid:17389308
|
Ishizuka K et al. |
Inhibitory effect of CGRP on osteoclast formation by mouse bone marrow cells treated with isoproterenol. |
2005 |
Neurosci. Lett. |
pmid:15814197
|
Shiota J et al. |
[Relationship between coronary and abdominal calcification score, serum osteoprotegerin (OPG), and serum tartrate-resistant acid phosphatase (TRACP) -5b in pre-dialysis CKD patients]. |
2010 |
Nihon Jinzo Gakkai Shi |
pmid:21254698
|
Kaneko K and Kawai S |
[Mechanisms and therapeutics of glucocorticoid-induced osteoporosis]. |
2011 |
Nihon Rinsho Meneki Gakkai Kaishi |
pmid:21720102
|
Tanaka Y et al. |
[Mesenchymal stem cells for the treatment and repair of inflammatory arthritis]. |
2015 |
Nihon Rinsho Meneki Gakkai Kaishi |
pmid:26016635
|
Kozaki K |
[Current concepts of vascular calcification]. |
2005 |
Nihon Ronen Igakkai Zasshi |
pmid:16408509
|
Suzuki Y |
[Clinical significance of biomarkers in diagnosis of metabolic bone diseases]. |
2007 |
Nippon Naika Gakkai Zasshi |
pmid:18044149
|
Kotake S et al. |
[Molecular mechanism of bone metabolism]. |
2000 |
Nippon Naika Gakkai Zasshi |
pmid:11215116
|
Tanaka Y and Okada Y |
[Progress in therapy and diagnosis: Hypercalcemia due to parathyroid hormone-related protein producing neoplasms]. |
2007 |
Nippon Naika Gakkai Zasshi |
pmid:17506302
|
Suda T and Miyaura C |
[Recent advance in basic research for osteoporosis]. |
2004 |
Nippon Rinsho |
pmid:15035090
|
Matsumoto T |
[Recent advances in the regulation of bone remodeling]. |
2004 |
Nippon Rinsho |
pmid:15035093
|
Okumura S et al. |
[Regulatory mechanism of osteoclast differentiation and function]. |
2004 |
Nippon Rinsho |
pmid:15035103
|
Tsuda E |
[Osteoclastogenesis inhibitory factor (OCIF)/OPG (a novel therapeutic candidate for the treatment of metabolic bone diseases)]. |
2002 |
Nippon Rinsho |
pmid:11979969
|
Udagawa N et al. |
[Possible role of RANKL in bone resorption]. |
2004 |
Nippon Rinsho |
pmid:15035104
|
Koshihara Y |
[Recent progress of bone cell culture system (review)]. |
2002 |
Nippon Rinsho |
pmid:11979973
|
Inoue D |
[OPG(osteoprotegerin)/OCIF(osteoclastogenesis inhibitory factor)]. |
2004 |
Nippon Rinsho |
pmid:15035105
|
Suzuki Y |
[Stimulator of bone resorption interleukin-1, interleukin-6 and gp-130 cytokine family]. |
2004 |
Nippon Rinsho |
pmid:15035106
|
Tsuda E and Higashio K |
[Osteoclastogenesis inhibitory factor (OCIF)/OPG]. |
1998 |
Nippon Rinsho |
pmid:9648461
|
Sato K |
[Osteoclast-activating factors (OAF)]. |
2004 |
Nippon Rinsho |
pmid:15658306
|
Chaki O |
[Osteoporosis]. |
2006 |
Nippon Rinsho |
pmid:16689336
|
Takahashi N et al. |
[Osteoprotegerin (OPG)]. |
2010 |
Nippon Rinsho |
pmid:20960766
|
Yasuda H |
[OPG, anti-rANKL antibody]. |
2005 |
Nippon Rinsho |
pmid:16164225
|
Takahashi N et al. |
[Osteoprotegerin (OPG)]. |
2005 |
Nippon Rinsho |
pmid:16149650
|
Takayanagi H |
[Cross-talk between immune and skeletal systems]. |
2002 |
Nippon Rinsho |
pmid:12510352
|
Nakamura M et al. |
[Osteoclastogenesis and bone resorption]. |
2009 |
Nippon Rinsho |
pmid:19432105
|
Masuda H and Tanaka S |
[Drugs under development for osteoporosis ]. |
2009 |
Nippon Rinsho |
pmid:19432120
|